

SOPHiA DDM™ Deployment for BioPharma

Expanding equitable access to precision medicine worldwide

Next-generation sequencing (NGS) is transforming cancer care and biomarker-driven treatment decisions, yet uneven global adoption, driven by workflows, limited expertise, and operational constraints, still limits the availability of accurate biomarker testing essential to expand patient access and ensure the success of targeted therapies.

SOPHiA GENETICS enables scalable, high-quality genomic testing worldwide, empowering local laboratories, **supporting global CDx development strategies, reducing equity gaps in cancer care, and helping BioPharma companies de-risk development and maximize the value of precision therapy programs.**

Maximizing post-market success with global deployment

TEST IMPLEMENTATION



Set institutions up for success

- Support the rapid implementation of high-quality NGS assay via SOPHiA DDM™ MaxCare Program
- Increase laboratory confidence in results through standardized workflows
- Build an infrastructure to reliably help identify patients eligible for targeted therapies

SPONSORED TESTING



Address access & reimbursement barriers

- Sponsor routine testing where a reimbursement structure is not yet established
- Equip laboratories with the resources for optimal test adoption
- Support accelerated patient access to newly launched biomarker-driven therapies

MEDICAL AWARENESS



Drive adoption and impact

- Educate and engage medical professionals
- Build trust in novel technologies and biomarkers
- Support guideline inclusion and impact testing behaviours for maximum patient benefit

SOPHiA DDM™ MaxCare Program

The SOPHiA DDM™ MaxCare Program is designed to help laboratories close the gap in test implementation barriers.

The program empowers them to confidently and seamlessly adopt, validate, and integrate high-quality NGS assays, expanding patient access to precision diagnostics and benefiting from targeted therapies.



An industry-leading implementation program



Dedicated local representatives

supporting the onboarding of new labs and SOPHiA DDM™ solutions



Proficiency data generated to ensure the robustness and accuracy of the test and workflow



Customized hands-on support, aligned with each lab experience including hospitals, reference labs, CROs and Pharma



Enabled workflow efficiency, supporting lab's self-validation and accreditation while reducing time to routine

Comprehensive support at every step



Feasibility
Assessment



Strategic
Consultation



Training



Assessment



Support
Documentation

Want to know more about our BioPharma offerings?

[GET IN TOUCH >](#)

© 2026 SOPHiA GENETICS. All rights reserved. All product and company names are trademarks™ or registered® trademarks of their respective holders. Use of them does not imply any affiliation with or endorsement by them. The information included in this flyer has been prepared for and is intended for viewing by a global audience. This flyer contains information about products which may or may not be available in different countries and if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. SOPHiA DDM™ MaxCare Program is an implementation program designed to empower local laboratory teams to accurately adopt a new NGS-based solution, according to each laboratory needs and the regulatory-grade of the selected assay.

